USP7

Molecure has published its financial report for 2023 - the company has significantly accelerated the development of its clinical and pre-clinical programmes and plans to make strong progress in research in 2024 and 2025

Retrieved on: 
Wednesday, April 3, 2024
Medical device, Annual report, ARG1, Documentation, Biotechnology, Sarcoidosis, Partnership, Patient, Scientific Research Publishing, USP7, Ethics, SPO, Biomarker, Research, Health care, Conception, Cancer, Messenger, POC, PLN, Biology, Royal, MHRA, Polish, Clinical trial, Safety, MOC, Phase, ARG2, Food, FDA, SMART, CDA, Pharmaceutical industry

We initiated clinical trials of our drug candidate, which was discovered and brought into clinical trials for cancer patients by Molecure.

Key Points: 
  • We initiated clinical trials of our drug candidate, which was discovered and brought into clinical trials for cancer patients by Molecure.
  • In 2023, our focus was also on preparing for a Phase II clinical trial for OATD 01, Molecure's flagship clinical programme.
  • We are very pleased to report that the first patient has started dosing in a clinical trial at a clinical site in the UK.
  • The Company plans to obtain further grants for projects within the framework of the pipeline developed so far.

Foundation for USP7 Related Diseases Announces Grant to Neurolentech in Search for Cure to Rare Disease Hao-Fountain Syndrome

Retrieved on: 
Monday, April 5, 2021
USP7, Genetic disorder, Disease, Articles

FALMOUTH, Maine, April 5, 2021 /PRNewswire/ -- The Foundation for USP7 Related Diseases (usp7.org) today announceda new research grant award to Neurolentech in a search for a cure to the rare disease Hao-Fountain Syndrome.

Key Points: 
  • FALMOUTH, Maine, April 5, 2021 /PRNewswire/ -- The Foundation for USP7 Related Diseases (usp7.org) today announceda new research grant award to Neurolentech in a search for a cure to the rare disease Hao-Fountain Syndrome.
  • Hao-Fountain Syndrome is a rare genetic disorder caused by mutations in the USP7 gene, with just 80 known patients worldwide.
  • We are thrilled to work together with patients and their families in order to advance the best research for USP7 related diseases.
  • The Foundation for USP7 Related Diseases was started in 2017 by a group of parents of affected children.

PMV Pharma Appoints p53 Pioneer Dr. Guillermina Lozano to Scientific Advisory Board

Retrieved on: 
Tuesday, February 16, 2021
Branches of biology, Proteins, Tumor suppressor genes, Mdm2, Oncogenes, P53, Tumor suppressor, MDM4, USP7, Mir-605 microRNA precursor family

"Gigis work in p53 biology has had a tremendous impact on our fundamental understanding of the p53 pathway and the consequences of p53 mutations in cancer, said David Mack, Ph.D., President and Chief Executive Officer of PMV Pharma.

Key Points: 
  • "Gigis work in p53 biology has had a tremendous impact on our fundamental understanding of the p53 pathway and the consequences of p53 mutations in cancer, said David Mack, Ph.D., President and Chief Executive Officer of PMV Pharma.
  • Dr. Guillermina (Gigi) Lozano is a geneticist recognized for her studies of the p53 tumor suppressor pathway, from characterizing p53 as a transcriptional activator to characterizing the physiological importance of Mdm2 and Mdm4 proteins as inhibitors of p53, and the consequences of p53 mutations on tumor development.
  • PMV Pharma is a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53 mutants.
  • Bringing together leaders in the field to exploit over four decades of p53 biology, PMV Pharma combines unique biological understanding with a pharmaceutical development focus.

Medivir enters into licensing agreement with Ubiquigent for preclinical program USP7

Retrieved on: 
Wednesday, February 10, 2021
Geography of Sweden, Municipalities of Sweden, Medivir, USP7, Stockholm

STOCKHOLM, Sweden, Feb. 10, 2021 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR) announced today that it had entered into a license agreement with Ubiquigent Limited (Ubiquigent) for Medivir's preclinical USP7 research program.

Key Points: 
  • STOCKHOLM, Sweden, Feb. 10, 2021 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR) announced today that it had entered into a license agreement with Ubiquigent Limited (Ubiquigent) for Medivir's preclinical USP7 research program.
  • - "We are very pleased that Medivir's research program aimed at the development of USP7 inhibitors has been licensed to Ubiquigent.
  • With an excellent track-record and strong research capabilities within the DUB field, we believe that Ubiquigent is perfectly positioned to further progress the USP7 program.
  • - "This agreement with Medivir is a tremendous endorsement of our approach and represents a significant milestone for Ubiquigent.

Almac Discovery to Present Updates on Key Oncology Programmes at the 2020 American Association for Cancer Research (AACR) Virtual Annual Meeting II

Retrieved on: 
Thursday, June 18, 2020
Branches of biology, Proteins, USP7, Mdm2, Transcription factors, Apoptosis, Programmed cell death, P53

Both programmes are advancing towards the nomination of candidate drugs, and the new data highlight significant progress that has been made in the last year towards this goal.

Key Points: 
  • Both programmes are advancing towards the nomination of candidate drugs, and the new data highlight significant progress that has been made in the last year towards this goal.
  • In addition to the established modulation of the p53/MDM2 pathway in cancer cells, this important finding supports new opportunities for combining USP7 inhibitors with immune modulators.
  • We are delighted to share our recent discovery differentiating USP7 inhibition from MDM2 antagonists at the upcoming AACR Virtual Annual Meeting."
  • Title: Discovery of a novel function for USP7 inhibitors: Reprogramming the tumour microenvironment